Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (âKSFâ) are investigating the propo
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Organon & Co. (NYSE: OGN) to Sun Pharmaceutical Industries Limited. Under the terms of the proposed transaction, shareholders of Organon will receive $14.00 in cash for each share of Organon that they own. KSF is seeking to determine whether this consideration and the process that led to it.
KIRKLAND, Quebec & SHANGHAI--(BUSINESS WIRE)--Organon Canada and Henlius expand access to denosumab treatments with launch of BILDYOS® and TUZEMTY® biosimilars to PROLIA and XGEVA.
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon completes agreement to license MIUDELLA®, Sebela's hormone-free IUD, expanding its long-acting reversible contraception portfolio.
INCHEON, South Korea & KIRKLAND, Quebec--(BUSINESS WIRE)--Organon and Samsung Bioepis expand agreement to commercialize PYZCHIVA® (ustekinumab), a biosimilar referencing STELARA® (ustekinumab) in Canada.
Organon said on Wednesday the U.S. Food and Drug Administration has approved the expanded use of its arthritis drug, a biosimilar to Roche's Actemra, to treat a life‑threatening immune reaction in some cancer patients and COVID-19 in patients needing breathing support.